Zhaoke Ophthalmology Completes Patient Enrollment for Phase III Trials of TAB014 and Epinastine
Zhaoke Ophthalmology Ltd (HKG: 6622), a former subsidiary of Lee’s Pharmaceutical Holdings Ltd (HKG: 0950),...
Amicus Therapeutics Secures FDA Approval for Pombiliti and Opfolda Combination Therapy
Amicus Therapeutics (NASDAQ: FOLD), headquartered in the United States, has announced that it has received...
Vela Diagnostics Partners with SRL Inc. to Expand Molecular Diagnostics in Japan
Singapore-based Vela Diagnostics, a global leader in integrated molecular solutions for diagnosing infectious diseases and...
Transcenta Secures FDA Approval for Phase III Trial of Osemitamab
China-based Transcenta Holding Ltd (HKG: 6628) has announced that it has received approval from the...
Shanghai Boosts Community Healthcare with Enhanced Reimbursement and Services
Shanghai’s healthcare security administration has announced a comprehensive set of measures aimed at enhancing community...
Novo Nordisk and Evotec Launch LAB eN² to Accelerate Drug Discovery for Rare Diseases
Global healthcare company Novo Nordisk (NYSE: NVO) and drug discovery alliance Evotec (NASDAQ: EVO) have...
Roche Secures Global Rights to Ionis Pharmaceuticals’ Alzheimer’s and Huntington’s Disease Candidates
Swiss pharmaceutical giant Roche (SWX: ROG) has announced the acquisition of global rights to develop,...
Takeda Receives FDA Approval for Subcutaneous Entyvio as UC Maintenance Therapy
The US Food and Drug Administration (FDA) has granted Japan’s Takeda Pharmaceuticals (TYO: 4502) regulatory...
Neusoft Medical’s NeuRT Aurora Receives NMPA Approval for Advanced Radiotherapy Platform
Neusoft Medical Systems Co., Ltd, a leading player in the medical technology sector, has announced...
CStone Pharmaceuticals’ PDGFRA Mutation Detection Kit Receives NMPA Approval
CStone Pharmaceuticals (HKG: 2616), a China-based biopharmaceutical company, has announced that it has received marketing...
RemeGen and Akeso Biopharma Initiate Phase II Study for Gastric Cancer Combo Therapy
China-based RemeGen Ltd (HKG: 9995) is poised to conduct a Phase II clinical study in...
Eli Lilly’s Insulin Biosimilar YouBiAn Approved for Diabetes Treatment in China
US pharmaceutical major Eli Lilly (NYSE: LLY) has announced that it has received market approval...
Everest Medicines’ Xerava Receives Marketing Approval from TFDA for cIAI Treatment
Everest Medicines (HKG: 1952) has announced that it has received marketing approval for its antibiotic...
Sino Medical Sciences Receives Turkish Approval for HT Supreme Drug-Eluting Stent System
Sino Medical Sciences Technology Inc., (SHA: 688108), a leading Chinese medical device company, has announced...
Konruns Pharmaceutical’s KC1036 Pediatric Indication Accepted for NMPA Review
Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has announced that the National Medical Products Administration...
Elpiscience Biopharmaceuticals Initiates Phase I Trial for Anti-LILRB2 Antibody ES009
Elpiscience Biopharmaceuticals, a China-based biopharmaceutical company, has announced that the first patient has been dosed...
Triastek Inc. Secures $20.5 Million in Pre-Series C Financing for 3D Printing Pipeline
China-based Triastek Inc., a company at the forefront of pharmaceutical-focused 3D printing, has reportedly secured...
Tasly Pharmaceuticals Gets NMPA Approval for B1344 Clinical Study in NASH
Tasly Pharmaceuticals (SHA: 600535), a China-based pharmaceutical company, has announced that it has received approval...
ImmuneOnco Initiates Phase I Trial for CD24-Targeted Monoclonal Antibody IMM47
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced the first patient dosing in a...
MitrAssist Lifesciences Secures $100 Million in Series C Financing for Cardiovascular Devices
MitrAssist Lifesciences Ltd, a Shanghai-based innovator in cardiovascular device manufacturing, has reportedly raised nearly USD...